Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - haemophilus type b polysaccharide, quantity: 10 microgram; tetanus protein, quantity: 18 microgram - injection, powder for - excipient ingredients: trometamol; sucrose - for use in infants from 2 months to 5 years of age for active immunization against invasive disease caused by the haemophilus influenzae type b.

Philippines - English - FDA (Food And Drug Administration)

phil pharmawealth, inc.; distributor: phil pharmawealth, inc. - famotidine - lyophilized powder for injection (iv) - 20 mg

Philippines - English - FDA (Food And Drug Administration)

phil pharmawealth, inc.; distributor: phil pharmawealth, inc. - inactivated purified rabies vaccine (vero-cell) - lyophilized powder for injection (id/im) - 2.5 iu

Philippines - English - FDA (Food And Drug Administration)

phil pharmawealth, inc.; distributor: phil pharmawealth, inc. - omeprazole (as sodium) - lyophilized powder for injection (i.v.) - 40mg

Philippines - English - FDA (Food And Drug Administration)

phil pharmawealth, inc.; distributor: phil pharmawealth, inc. - omeprazole (as sodium) - lyophilized powder for injection (i.v.) - 40 mg

Philippines - English - FDA (Food And Drug Administration)

phil. pharmawealth, inc.; distributor: phil. pharmawealth, inc. - remdesivir (drug product for emergency use only) - lyophilized powder for solution for infusion (i.v.) - 100 mg

United States - English - NLM (National Library of Medicine)

merck sharp & dohme corp. - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen (unii: luy6p8763w) (haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen - unii:luy6p8763w) - haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen 1 g in 1 g

United States - English - NLM (National Library of Medicine)

glaxosmithkline biologicals sa - haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen (unii: c9r35m8xv6) (haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen - unii:c9r35m8xv6) - haemophilus influenzae type b strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen 10 ug in 0.5 ml - hiberix is indicated for active immunization for the prevention of invasive disease caused by haemophilus influenzae (h. influenzae) type b. hiberix is approved for use in children aged 6 weeks through 4 years (prior to fifth birthday). severe allergic reaction (e.g., anaphylaxis) after a previous dose of any h. influenzae type b- or tetanus toxoid-containing vaccine or any component of the vaccine is a contraindication to administration of hiberix [see description (11)] . safety and effectiveness of hiberix in children younger than 6 weeks and in children aged 5 to 16 years have not been established.

Philippines - English - FDA (Food And Drug Administration)

glaxosmithkline philippines, inc. - haemophilus influenza type b conjugate vaccine - lyophilized powder for injection - 10mcg + 0.5ml